Related Experiment Video
Updated: Jun 7, 2026

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Sympathetic blockade prevents the decrease in cardiac VEGF expression and capillary supply in experimental renal
1Department of Pathology, University of Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany. kerstin.amann@uk-erlangen.de
Insights
Kidney failure reduces cardiac vascular endothelial growth factor (VEGF) in rats, impairing heart function. Blocking the sympathetic nervous system may improve cardiac VEGF levels and heart health.
Area of Science:
- Cardiovascular research
- Renal disease mechanisms
- Molecular biology
Background:
- Uremic cardiomyopathy is linked to reduced myocardial capillary supply.
- Sympathetic nervous system blockade can prevent cardiac issues in uremic rats.
- The role of vascular endothelial growth factor (VEGF) in uremic cardiomyopathy is unclear.
Purpose of the Study:
- To investigate if cardiac vascular endothelial growth factor (VEGF) gene and protein expression are altered in experimental renal failure.
- To determine the effect of sympathetic nervous system downregulation on cardiac VEGF expression and myocardial capillary supply in rats with renal failure.
Main Methods:
- Long-term study: Compared VEGF gene and protein expression and capillary supply in Sprague-Dawley rats with subtotal nephrectomy (SNX) versus sham operation.
- Short-term study: Analyzed the effect of renal denervation on cardiac VEGF, flt-1, and flk-1 gene expression and myocardial capillary supply in SNX rats.
Main Results:
- Long-term: SNX rats showed significantly lower cardiac capillary supply and VEGF gene/protein expression compared to sham rats.
- Short-term: Untreated SNX rats had significantly lower cardiac VEGF mRNA expression than sham rats.
- Renal denervation prevented the decrease in cardiac VEGF mRNA expression in SNX rats.
Conclusions:
- Cardiac VEGF gene and protein expression are reduced in experimental renal failure.
- Reduced cardiac VEGF may contribute to impaired myocardial adaptation and hypertrophy in renal failure.
- Sympathetic nervous system downregulation may improve cardiac structure and function in renal failure partly via increased cardiac VEGF expression.
Abstract:
Uremic cardiomyopathy of men and rodents is characterized by lower myocardial capillary supply that in rats could be prevented by central and peripheral blockade of the sympathetic nervous system. The underlying pathomechanisms remain largely unknown. We investigated whether alterations of cardiac vascular endothelial growth factor (VEGF) gene and protein expression were involved. In our long-term experiment, we analyzed whether VEGF gene and protein expression was altered in the heart of male Sprague-Dawley rats with either sham operation (sham, n=10) or subtotal nephrectomy (SNX, n=10). In our short-term experiment (17 sham, 24 SNX), the effect of a putative downregulation of sympathetic nervous activity by surgical renal denervation (interruption of renal afferent pathways) on cardiac gene expression of VEGF, flt-1, and flk-1 and on myocardial capillary supply was analyzed. In the long-term study, cardiac capillary supply and vascular endothelial growth factor gene and protein expression were significantly lower in SNX than in sham. In the short-term experiment, cardiac VEGF mRNA expression was significantly lower in untreated SNX (4,258±2,078 units) than in both sham groups (11,709±4,169 and 8,998±4,823 units); this decrease was significantly prevented by renal denervation (8,190±3,889, P<0.05). We conclude that cardiac VEGF gene and protein expression is reduced in experimental renal failure, and this may be considered as one potential reason for impaired myocardial adaptation under the situation of cardiac hypertrophy. The beneficial effect of sympathetic downregulation on cardiac structure and function in renal failure may be at least in part explained by increased cardiac VEGF gene expression.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Heart Failure II: Pathophysiology
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

